Page 33 - COVID-19-Mortality-review-in-Malaysia-and-updates-on-clinical-management-of-COVID-19

Remdesivir for the treatment of COVID-19: results,

days to recovery

The data showed that the ones (mild - moderate category) that did not require oxygen,
the outcome was no different between the Remdesivir and placebo groups [7]. They

were looking at the days to recovery, meaning how many days it took to go back to
category 1 and 2. At least 2 categories had pointed to less days to recover because the
study was published so fast that they couldn't look at mortality data yet. The overall

study showed that the patients who took Remdesivir became well faster, at day 11
while patients who took placebo became well slower. It took 15 days. Most of the data
was in the severe groups where it took 12 days to recover for the Remdesivir group and

18 days in the placebo group. There was no difference in the two groups that did not
require oxygen (mild - moderate disease groups). So, the question is whether the

milder group ever needs to give them antivirals or not?

Diagram 15: Comparison of Remdesivir and placebo treatment arm in terms of

days to recovery and severity of COVID-19 disease.